AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12604544
Drug: Valacyclovir (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (both treatment regimens)
Trial: 29860335
Drug: Betaine 3300
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine 3300 mg orally twice daily for 10 days, then 4950 mg twice daily for 12 weeks
Trial: 22757968
Drug: External Qigong
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Qigong Therapy (EQT)
Trial: 18654733
Drug: Sham Treatment
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Treatment (Control)
Trial: 12494034
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg/day) for 1 month
Trial: 12494034
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 mg/day) in 5 patients
Trial: 3782679
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 0.5 mg epinephrine
Trial: 8618182
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (52 micromol or 50,000 IU orally administered at birth)
Trial: 2016833
Drug: Antibiotic-bonded catheters
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-bonded catheters (pretreated with tridodecylmethylammonium chloride and immersed in a 50-mg/mL cefazolin solution)
Trial: 26393910
Drug: American ginseng
RxNorm normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: American ginseng tea infusion
Trial: 18214192
Drug: Zinc cream
RxNorm normalized name: CARRINGTON MOISTURE BARRIER/ZINC CREAM
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc cream
Trial: 21854132
Drug: Clindamycin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (300 mg twice a day/week)
Trial: 17593672
Drug: Steam inhalation
RxNorm normalized name: Leader Hot Steam Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steam inhalation (Control)
Trial: 8085464
Drug: Moclobemide (300‐450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300‐450 mg/day)
Trial: 10220121
Drug: Fluoxetine (20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20‐40 mg/day)
Trial: 2751139
Drug: 0.067 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.067 mg.kg‐1 caudal morphine
Trial: 2751139
Drug: 0.10 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 mg.kg‐1 caudal morphine
Trial: 1098499
Drug: Amodiaquine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (2.0 g course)
Trial: 31576433
Drug: Nivolumab 960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 960 mg
Trial: 28295989
Drug: 5 mg/ml
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/ml liquid formulation of 6-mercaptopurine (6-MP)
Trial: 28295989
Drug: 50 mg/ml
RxNorm normalized name: urea 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/ml liquid formulation of 6-mercaptopurine (6-MP)
Trial: 28295989
Drug: Marketed 50
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed 50 mg 6-MP tablet
Trial: 25181451
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) starting titration at 200 μg
Trial: 25181451
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) starting titration at 100 μg
Trial: 25181451
Drug: Effective doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective doses of FBT
Trial: 25181451
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal tablet (FBT) at doses up to 800 μg
Trial: 24490266
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg daily for 18 months)
Trial: 15252267
Drug: Modafinil 400-mg
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 400-mg once daily (7 AM) plus placebo (noon)
Trial: 15252267
Drug: Modafinil (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (both dosing strategies)
Trial: 11511287
Drug: Atropine 1%
RxNorm normalized name: Isopto Atropine 1% Ophthalmic Solution
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine 1% ophthalmic solution
Trial: 8016009
Drug: Naftopidil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftopidil (50 mg, oral administration)
Trial: 8016009
Drug: Naftopidil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftopidil (5 mg, intravenous infusion)
Trial: 2648152
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml or 50 ml of fish oil (3 or 15 g of n‐3 fatty acids)
Trial: 2648152
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of safflower oil (39 g of n‐6 fatty acids)
Trial: 21546277
Drug: 3-day conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day conventional bowel preparation (BP) method: diet restriction, oral antibiotics, oral laxatives, and saline enemas over a 3-day period.
Trial: 16859579
Drug: Subcutaneous interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interleukin-2 (IL-2) at dose level 3: 4 MIU/m2 per day, weeks 1-4, 9-12, and 17-20 (n = 11)
Trial: 9312310
Drug: Bicalutamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (50 mg) after food
Trial: 9312310
Drug: Bicalutamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (50 mg) after fasting
Trial: 29098249
Drug: Free dental
RxNorm normalized name: CariFree Dental Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free dental filling intervention (oral health examination and free filling of shallow and moderate caries once a year for 3 years)
Trial: 23437905
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education and training (lecture and hands-on training)
Trial: 8877932
Drug: Lornoxicam 4
RxNorm normalized name: lornoxicam 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 4 mg tid (follow-up)
Trial: 8877932
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg bid (follow-up)
Trial: 1642079
Drug: Intermediate-acting insulin
RxNorm normalized name: Intermediate-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-acting insulin twice daily (2-dose)
Trial: 1642079
Drug: Preprandial regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprandial regular insulin and intermediate-acting insulin at bedtime (4-dose)
Trial: 1642079
Drug: Oral hypoglycemic
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemic agents (before insulin treatment)
Trial: 22313548
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus glycoprotein IIb/IIIa inhibitor (H-GPI)
Trial: 16936707
Drug: Intranasal regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal regular human insulin (RH‐I) 40 IU acute and 4 x 40 IU/day over 8 weeks
Trial: 25285572
Drug: Protease inhibitors
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitors (PI)
Trial: 23484100
Drug: Fosteum (27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosteum (27 mg natural genistein, 200 IU cholecalciferol, 20 mg citrated zinc bisglycinate)
Trial: 23484100
Drug: Squadrito formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squadrito formulation (27 mg natural genistein, 400 IU cholecalciferol, 500 mg elemental calcium)
Trial: 23484100
Drug: Citracal Plus
RxNorm normalized name: Citracal Plus with Magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citracal Plus Bone Density Builder (27 mg synthetic genistein, 600 mg elemental calcium, 400 IU vitamin D3, 50 mg magnesium, 7.5 mg zinc, 1 mg copper, 75 μg molybdenum, 250 μg boron)
Trial: 18785964
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of triamcinolone acetonide (4 mg)
Trial: 11342699
Drug: Dual-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-release formulation of L-dopa plus benserazide
Trial: 11342699
Drug: Slow-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release formulation of L-dopa plus benserazide
Trial: 7713100
Drug: Quinapril 5
RxNorm normalized name: quinapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 5 mg b.i.d.
Trial: 2455118
Drug: nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (10 mg p.o.)
Trial: 10891434
Drug: Filgrastim (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (10 microg/kg daily)
Trial: 1546139
Drug: Moclobemide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (150 mg t.i.d.)
Trial: 1546139
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg t.i.d.)
Trial: 29676440
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m2/dose)
Trial: 21750974
Drug: CHO gel
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO gel ingestion
Trial: 18165400
Drug: Titrated oral
RxNorm normalized name: magnesium citrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oral misoprostol
Trial: 16026367
Drug: Liraglutide 0.045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.045 mg
Trial: 16026367
Drug: Liraglutide 0.225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.225 mg
Trial: 15161785
Drug: Liraglutide 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.75 mg
Trial: 19853906
Drug: Liraglutide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (all doses)
Trial: 12450642
Drug: Hydrocortisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (50 mg orally)
Trial: 6352659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cephalothin, carbenicillin and gentamicin
Trial: 31302943
Drug: Oral Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tranexamic Acid (TA) 1,500 mg daily for 6 weeks
Trial: 9387206
Drug: Aspirin, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 100 mg daily
Trial: 20150175
Drug: Magnetic-activated cell
RxNorm normalized name: Activated natural killer cell therapy
DrugBank: Activated natural killer cell therapy (DB17172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic-activated cell sorting (MACS) for sperm preparation (D + M)
Trial: 15465628
Drug: Pre-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment with guanine nucleotides (GTP)
Trial: 9637638
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil at a dosage of 0.1 microg kg(‐1) x min(‐1) until skin closure
Trial: 3288460
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pirenzepine
Trial: 2886245
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg famotidine
Trial: 2904218
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg famotidine plus 50 mg pirenzepine
Trial: 21756812
Drug: Milrinone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (5 mg diluted in 5 ml normal saline inhaled every 8 hours for two days pre-operation)
Trial: 21756812
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 ml normal saline inhaled)
Trial: 19637941
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg twice/day
Trial: 19637941
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (various doses: 25, 50, 100, 200 mg once/day)
Trial: 19637941
Drug: Carvedilol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (various doses: 3.125, 6.25, 12.5, 25 mg twice/day)
Trial: 10357747
Drug: 60 or
RxNorm normalized name: QM-260 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 or 120 mg Fe plus 3.5 mg folic acid weekly for 22 weeks
Trial: 7012343
Drug: Group counseling
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group counseling and education (12 weekly sessions)
Trial: 29401177
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg oral)
Trial: 29418049
Drug: SBIRT program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBIRT program (brief motivational intervention on alcohol use and referral to specialized treatment)
Trial: 22663011
Drug: trametinib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trametinib (2 mg orally once daily)
Trial: 22663011
Drug: chemotherapy (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy (intravenous dacarbazine 1000 mg/m² or paclitaxel 175 mg/m² every 3 weeks)
Trial: 15854844
Drug: Estimation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimation of lung tumor volumes during radiotherapy treatment planning.
Trial: 11248608
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER 4 mg once daily
Trial: 2541193
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg by pressurized aerosol)
Trial: 19037613
Drug: Lomotil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomotil (5 mg diphenoxylate hydrochloride/0.05 mg atropine sulfate)
Trial: 19037613
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL water (control group)
Trial: 2502837
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg, single oral dose)
Trial: 2502837
Drug: Amoxycillin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (3 g) and Probenecid (1 g, single oral dose)
Trial: 1269432
Drug: Nitroprusside infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside infusion at 20 mug/min in group I
Trial: 1269432
Drug: Nitroprusside infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside infusion at 20 mug/min in group II
Trial: 1269432
Drug: Nitroprusside infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside infusion in group I
Trial: 30797492
Drug: GC +
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC + N (necitumumab 800 mg on days 1 and 8 of a 3-week cycle, gemcitabine 1250 mg/m2 on days 1 and 8, cisplatin 75 mg/m2 on day 1)
Trial: 30797492
Drug: GC (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC (gemcitabine 1250 mg/m2 on days 1 and 8, cisplatin 75 mg/m2 on day 1)
Trial: 25297337
Drug: Adenosine/verapamil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine/verapamil (40 mg orally after converting to sinus rhythm)
Trial: 25297337
Drug: Adenosine only
RxNorm normalized name: Adenosine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine only (6 mg rapid bolus intravenous injection followed by two repeated doses of 12 mg if necessary)
Trial: 29793565
Drug: Topical liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical liposomal thermo-sensitive gel (TLTG)
Trial: 25795459
Drug: Pre-operative occupational
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative occupational therapy intervention (home visit by an occupational therapist)
Trial: 26300269
Drug: Postoperative SSA
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative SSA treatment
Trial: 26300269
Drug: Postoperative pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Postoperative pegvisomant treatment
Trial: 23609368
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (200 µg)
Trial: 16751162
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intrathecal morphine)
Trial: 15587094
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (0.3 mg/kg)
Trial: 19021008
Drug: 0.5mg/kg ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg/kg ketamine by intravenous route before induction
Trial: 19021008
Drug: 0.7 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/kg 0.2% ropivacaine caudally and 2ml normal saline intravenously
Trial: 19021008
Drug: 0.7 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/kg 0.2% ropivacaine caudally and 0.5mg/kg ketamine by intravenous route
Trial: 16640101
Drug: combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination therapy (peg-IFN-alpha2a and 3TC)
Trial: 11050695
Drug: Onion-olive-oil maceration
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onion-olive-oil maceration capsule formulation
Trial: 8351023
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 to 150 mg/d
Trial: 3717537
Drug: Morphine orally
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine orally and scopolamine transdermally
Trial: 3717537
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine and scopolamine
Trial: 22775130
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of rumination in response to unpleasant daily events
Trial: 22775130
Drug: Lower use
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower use of rumination in response to unpleasant daily events
Trial: 9758242
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg daily
Trial: 18725220
Drug: Sibutramine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (10 or 15 mg)
Trial: 2662354
Drug: Praziquantel 60
RxNorm normalized name: praziquantel 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 60 mg daily dose
Trial: 2662354
Drug: Praziquantel 75
RxNorm normalized name: METRONIDAZOLE 250 mg in 2 g / PRAZIQUANTEL 75 mg in 2 g TOPICAL POWDER [API General Cure]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 75 mg daily dose in 15-29 year old patients
Trial: 29214645
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg.kg‐1
Trial: 29214645
Drug: Neostigmine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 40 μg.kg‐1 and glycopyrrolate 400 μg
Trial: 20800380
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy with daily 18 fractions (Arm 2)
Trial: 20800380
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy with twice-daily 24 fractions (Arm 3)
Trial: 17124621
Drug: escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram 20 mg + pindolol (5-HT(1a) antagonist) 10 mg
Trial: 17124621
Drug: escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram 20 mg + ketanserin (5-HT(2a) antagonist) 50 mg
Trial: 15134388
Drug: Stabilized oral
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilized oral NADH (10 mg/day)
Trial: 11772296
Drug: Tissue factor
RxNorm normalized name: Tissue factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue factor pathway inhibitor (TFPI)
Trial: 9619701
Drug: Lubeluzole 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole 7.5 mg over 1 h followed by 10 mg/day for up to 5 days